These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37051238)

  • 41. A Mitophagy-Related Gene Signature for Subtype Identification and Prognosis Prediction of Hepatocellular Carcinoma.
    Liu C; Wu Z; Wang L; Yang Q; Huang J; Huang J
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36292980
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Construction of a prognostic risk model based on apoptosis-related genes to assess tumor immune microenvironment and predict prognosis in hepatocellular carcinoma.
    Wang X; Ji C
    BMC Gastroenterol; 2022 Aug; 22(1):400. PubMed ID: 36028814
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
    Jiang H; Ning G; Wang Y; Lv W
    Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An immune-related biomarker index for predicting the effectiveness of immunotherapy and prognosis in hepatocellular carcinoma.
    Wu X; Jin B; Liu X; Mao Y; Wan X; Du S
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10319-10333. PubMed ID: 37273105
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of a Five Immune Term Signature for Prognosis and Therapy Options (Immunotherapy versus Targeted Therapy) for Patients with Hepatocellular Carcinoma.
    Bin X; Luo Z; Wang J; Zhou S
    Comput Math Methods Med; 2023; 2023():8958962. PubMed ID: 36785674
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comprehensive analysis of the amino acid metabolism-related gene signature for prognosis, tumor immune microenvironment, and candidate drugs in hepatocellular carcinoma.
    Li Y; Mo H; Jia S; Wang J; Ma Y; Liu X; Tu K
    Front Immunol; 2022; 13():1066773. PubMed ID: 36582227
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cuproptosis regulator-mediated patterns associated with immune infiltration features and construction of cuproptosis-related signatures to guide immunotherapy.
    Wang G; Xiao R; Zhao S; Sun L; Guo J; Li W; Zhang Y; Bian X; Qiu W; Wang S
    Front Immunol; 2022; 13():945516. PubMed ID: 36248857
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Deciphering a mitochondria-related signature to supervise prognosis and immunotherapy in hepatocellular carcinoma.
    Shi Y; Huang G; Jiang F; Zhu J; Xu Q; Fang H; Lan S; Pan Z; Jian H; Li L; Zhang Y
    Front Immunol; 2022; 13():1070593. PubMed ID: 36544763
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of cancer-associated fibroblasts signature for predicting the prognosis and immunotherapy response in hepatocellular carcinoma.
    Ye J; Tian W; Zheng B; Zeng T
    Medicine (Baltimore); 2023 Nov; 102(45):e35938. PubMed ID: 37960718
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Construction and Validation of an Epigenetic Regulator Signature as A Novel Biomarker For Prognosis, Immunotherapy, And Chemotherapy In Hepatocellular Carcinoma.
    Cai J; Wu S; Zhang F; Dai Z
    Front Immunol; 2022; 13():952413. PubMed ID: 35911718
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Differentiation-Related Gene Prognostic Index Contributes to Prognosis and Immunotherapy Evaluation in Patients with Hepatocellular Carcinoma.
    Xiao J; Liu T; Liu Z; Xiao C; Du J; Zuo S; Li H; Gu H
    Cells; 2022 Jul; 11(15):. PubMed ID: 35892599
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma.
    Liu Z; Zhang Y; Shi C; Zhou X; Xu K; Jiao D; Sun Z; Han X
    J Transl Med; 2021 Jan; 19(1):5. PubMed ID: 33407585
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Implications of m6A-associated snRNAs in the prognosis and immunotherapeutic responses of hepatocellular carcinoma.
    Zhang C; Zhang W; Shui Y; Li P; Tian Z; Duan S; Wei Q
    Front Immunol; 2022; 13():1001506. PubMed ID: 36405741
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Integrated analysis revealing a novel stemness-metabolism-related gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma.
    Wang Y; Wan X; Du S
    Front Immunol; 2023; 14():1100100. PubMed ID: 37622118
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exploration and validation of a novel prognostic signature based on comprehensive bioinformatics analysis in hepatocellular carcinoma.
    Wang X; Qiao J; Wang R
    Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33111935
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of molecular heterogeneity of hepatocellular carcinoma based on immune gene expression signatures.
    Lou X; Wang JJ; Wei YQ; He YJ; Jiang ZJ; Sun JJ
    Med Oncol; 2021 Mar; 38(5):50. PubMed ID: 33786682
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A necroptosis-related gene signature for predicting prognosis, immune landscape, and drug sensitivity in hepatocellular carcinoma.
    Chen J; Wang H; Zhou L; Liu Z; Chen H; Tan X
    Cancer Med; 2022 Dec; 11(24):5079-5096. PubMed ID: 35560794
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Construction of a Novel LncRNA Signature Related to Genomic Instability to Predict the Prognosis and Immune Activity of Patients With Hepatocellular Carcinoma.
    Zhu J; Huang Q; Liu S; Peng X; Xue J; Feng T; Huang W; Chen Z; Lai K; Ji Y; Wang M; Yuan R
    Front Immunol; 2022; 13():856186. PubMed ID: 35479067
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma.
    Li R; Zhao W; Liang R; Jin C; Xiong H
    Front Mol Biosci; 2022; 9():917839. PubMed ID: 35847972
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.